Literature DB >> 10378847

A survey of phlebotomy among persons with hemochromatosis.

S M McDonnell1, A J Grindon, B L Preston, J C Barton, C Q Edwards, P C Adams.   

Abstract

BACKGROUND: One in 10 whites in the United States is a carrier for hemochromatosis and an estimated 1 in 200 is clinically affected. Early treatment with therapeutic phlebotomy to remove excess iron can prevent associated chronic diseases. However, little information is available on the amount of blood withdrawn or the rates of withdrawal from hemochromatosis patients. The patterns of therapeutic phlebotomy and the magnitude of charges in persons with hemochromatosis were surveyed. STUDY DESIGN AND METHODS: Surveys were mailed to persons with hemochromatosis identified by health care providers, blood centers, patient advocacy groups, and the Internet. There were 2362 respondents to the survey from the United States.
RESULTS: Thirty-seven percent of respondents reported being voluntary blood donors prior to diagnosis. The mean rate of therapeutic phlebotomy for iron depletion was 2.6 units per month (mean duration, 13 months). The mean rate of maintenance phlebotomy was 0.5 units per month. Therapeutic phlebotomy rates varied by sex, age, reason for diagnosis, and severity of symptoms. Seventy-six percent of respondents reported full or partial insurance coverage of therapeutic phlebotomy charges. Seventy-six percent received therapeutic phlebotomy services in a hospital or physician's office and 30 percent in a blood center. Charges for therapeutic phlebotomy varied by site, with a mean cost of $90 in hospitals and $52 in blood centers. Fifty-four percent of respondents attempted to donate blood after their diagnosis but were excluded.
CONCLUSION: The amount of blood withdrawn from persons with hemochromatosis is substantial. The location where patients received phlebotomy services appears to be influenced by charges and time since diagnosis.

Entities:  

Mesh:

Year:  1999        PMID: 10378847     DOI: 10.1046/j.1537-2995.1999.39060651.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

Review 1.  Demanding pure motives for donation: the moral acceptability of blood donations by haemochromatosis patients.

Authors:  G Pennings
Journal:  J Med Ethics       Date:  2005-02       Impact factor: 2.903

Review 2.  Oral nucleic acid therapy using multicompartmental delivery systems.

Authors:  Husain Attarwala; Murui Han; Jonghan Kim; Mansoor Amiji
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

3.  Survival and development of health conditions after iron depletion therapy in C282Y-linked hemochromatosis patients.

Authors:  Paul C Adams; Lucie Richard; Matthew Weir; Mark Speechley
Journal:  Can Liver J       Date:  2021-11-11

Review 4.  Hemochromatosis. Common genes, uncommon illness?

Authors:  Helen Harrison; Paul C Adams
Journal:  Can Fam Physician       Date:  2002-08       Impact factor: 3.275

5.  GNPAT p.D519G is independently associated with markedly increased iron stores in HFE p.C282Y homozygotes.

Authors:  James C Barton; Wen-Pin Chen; Mary J Emond; Pradyumna D Phatak; V Nathan Subramaniam; Paul C Adams; Lyle C Gurrin; Gregory J Anderson; Grant A Ramm; Lawrie W Powell; Katrina J Allen; John D Phillips; Charles J Parker; Gordon D McLaren; Christine E McLaren
Journal:  Blood Cells Mol Dis       Date:  2016-11-12       Impact factor: 3.039

6.  Renal clearable nanochelators for iron overload therapy.

Authors:  Homan Kang; Murui Han; Jie Xue; Yoonji Baek; JuOae Chang; Shuang Hu; HaYoung Nam; Min Joo Jo; Georges El Fakhri; Michael P Hutchens; Hak Soo Choi; Jonghan Kim
Journal:  Nat Commun       Date:  2019-11-13       Impact factor: 14.919

7.  Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators.

Authors:  Seung Hun Park; Richard S Kim; Wesley R Stiles; Minjoo Jo; Lingxue Zeng; Sunghoon Rho; Yoonji Baek; Jonghan Kim; Moon Suk Kim; Homan Kang; Hak Soo Choi
Journal:  Adv Sci (Weinh)       Date:  2022-03-27       Impact factor: 17.521

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.